Labcorp (LH)
(Delayed Data from NYSE)
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:10 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:10 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Is John Hancock Multifactor Mid Cap ETF (JHMM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JHMM
Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.
LabCorp (LH) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
LabCorp (LH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.
Here's Why You Should Retain Charles River (CRL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.
Best Growth Stocks to Buy for December 15th
by Zacks Equity Research
CC, LH, and HCCI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 15, 2021
Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.
Study Favors Masimo's (MASI) SedLine for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.
Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses
by Zacks Equity Research
Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.
Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm
by Zacks Equity Research
The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.
CVS Health (CVS) Outlines Growth Strategy, Initiates 2022 View
by Zacks Equity Research
CVS Health's (CVS) new strategy capitalizes on the considerable opportunity to make health care more convenient, personalized and affordable for consumers.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
PerkinElmer's (PKI) Latest Kit to Boost COVID-19 Surveillance
by Zacks Equity Research
PerkinElmer's (PKI) newest addition to its SARS-CoV-2 testing portfolio is expected to aid in combating the pandemic by boosting surveillance.
Edwards (EW) States Long-Term Strategy, Provides 2022 View
by Zacks Equity Research
Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.
Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.
QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer
by Zacks Equity Research
QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.
BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm
by Zacks Equity Research
BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.
Is LabCorp (LH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.
PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research
by Zacks Equity Research
PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable
by Zacks Equity Research
Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.
LH vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. WST: Which Stock Is the Better Value Option?
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.